Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
1. Pfizer agreed to lower U.S. drug prices and invest $70 billion in manufacturing. 2. President Trump ensures drugmakers three-year tariff exemption with pricing agreements. 3. Pfizer's Medicaid sales are under 5%, limiting the deal's overall impact. 4. Stock prices for Pfizer and peers rose post-agreement, signaling market relief. 5. Analysts expect more similar deals among major pharmaceutical firms soon.